AngioScore begins enrollment of AngioSculpt balloon catheter
AngioScore, a developer of novel angioplasty catheters, has successfully initiated the enrollment of its AGILITY trial, a study of AngioSculpt scoring, balloon catheter, multi-center coronary bifurcation.
The prospective, single are AGILITY trial will enroll 100 patients with coronary bifurcation lesions at eight U.S. interventional cardiology programs, and follow these patients for nine months, the Fremont, Calif.-based company said.
The study will evaluate the AngioSculpt Scoring Balloon as the primary treatment of the side-branch vessel along with an approved drug-eluting stent for the main branch vessel.
The company said that patients will be followed at one month for safety outcomes and at nine months for clinical evidence of restenosis.
Jeffrey Moses, MD, a professor of medicine and director of the cardiac catheterization laboratories at Columbia University Medical Center in New York City, will serve as the trial’s principal investigator.
The prospective, single are AGILITY trial will enroll 100 patients with coronary bifurcation lesions at eight U.S. interventional cardiology programs, and follow these patients for nine months, the Fremont, Calif.-based company said.
The study will evaluate the AngioSculpt Scoring Balloon as the primary treatment of the side-branch vessel along with an approved drug-eluting stent for the main branch vessel.
The company said that patients will be followed at one month for safety outcomes and at nine months for clinical evidence of restenosis.
Jeffrey Moses, MD, a professor of medicine and director of the cardiac catheterization laboratories at Columbia University Medical Center in New York City, will serve as the trial’s principal investigator.